Propofol Suppresses Prostaglandin E2 Production in Human Peripheral Monocytes

Immunopharmacology and Immunotoxicology

Volumn 31, Issue 1, 2009, Pages 117-126

  Kambara, Tomoko ^a   Inada, Takefumi ^a   Kubo, Kozue ^a   Shingu, Koh ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

cyclooxygenase; Propofol; prostaglandin E2

Indexed keywords

AMIDINE; ARACHIDONIC ACID; ARGININE; BENZYLAMINE DERIVATIVE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ENZYME INHIBITOR; IL10 PROTEIN, HUMAN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; N (3 (AMINOMETHYL)BENZYL)ACETAMIDINE; N-(3-(AMINOMETHYL)BENZYL)ACETAMIDINE; NITRIC OXIDE; NOS2A PROTEIN, HUMAN; PROPOFOL; PROSTAGLANDIN E2; PTGS1 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN; THROMBOXANE B2; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BIOCATALYSIS; BIOSYNTHESIS; CELL SURVIVAL; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; MONOCYTE;

AMIDINES; ARACHIDONIC ACID; ARGININE; BENZYLAMINES; BIOCATALYSIS; CELL SURVIVAL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DINOPROSTONE; ENZYME INHIBITORS; HUMANS; INTERLEUKIN-10; LIPOPOLYSACCHARIDES; MONOCYTES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PROPOFOL; THROMBOXANE B2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77449125357     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.1080/08923970802452046     Document Type: Article

References (50)

1. Mak, T. W.; Saunders, M. E. The immune response: Basic and clinical principles. Elsevier Academic Press, Burlington, MA, USA, 2006.
2. Kim, R.; Emi, M.; Tanabe, K.; Arihiro, K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 2006, 66 (11), 5527 – 5536.
3. Simmons, D. L.; Botting, R. M.; Hla, T. Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 2004, 56 (3), 387 – 437.
4. Bryn, T.; Yaqub, S.; Mahic, M.; Henjum, K.; Aandahl, E. M.; Tasken, K. LPS-activated monocytes suppress T-cell immune responses and induce FOXP3+ T cells through a COX-2-PGE2-dependent mechanism. Int. Immunol. 2008, 20 (2), 235 – 245.
5. Dubois, R. N.; Abramson, S. B.; Crofford, L.; Gupta, R. A.; Simon, L. S.; Van De Putte, L. B.; Lipsky, P. E. Cyclooxygenase in biology and disease. FASEB J. 1998, 12 (12), 1063 – 1073.
6. Smith, W. L.; DeWitt, D. L.; Garavito, R. M. Cyclooxygenases: Structural, cellular, and molecular biology. Annu. Rev. Biochem. 2000, 69, 145 – 182.
7. Stachowska, E.; Baskiewicz-Masiuk, M.; Dziedziejko, V.; Adler, G.; Bober, J.; Machalinski, B.; Chlubek, D. Conjugated linoleic acids can change phagocytosis of human monocytes/macrophages by reduction in Cox-2 expression. Lipids 2007, 42 (8), 707 – 716.
8. Harris, S. G.; Padilla, J.; Koumas, L.; Ray, D.; Phipps, R. P. Prostaglandins as modulators of immunity. Trends Immunol. 2002, 23 (3), 144 – 150.
9. Tilley, S. L.; Coffman, T. M.; Koller, B. H. Mixed messages: Modulation of inflammation and immune responses by prostaglandins and thromboxanes. J. Clin. Invest. 2001, 108 (1) 15 – 23.
10. Okano, M.; Sugata, Y.; Fujiwara, T.; Matsumoto, R.; Nishibori, M.; Shimizu, K.; Maeda, M.; Kimura, Y.; Kariya, S.; Hattori, H.; Yokoyama, M.; Kino, K.; Nishizaki, K. E prostanoid 2 (EP2)/EP4-mediated suppression of antigen-specific human T-cell responses by prostaglandin E2. Immunology 2006, 118 (3), 343 – 352.
11. Demeure, C. E.; Yang, L. P.; Desjardins, C.; Raynauld, P.; Delespesse, G. Prostaglandin E2 primes naive T cells for the production of anti-inflammatory cytokines. Eur. J. Immunol. 1997, 27 (12), 3526 – 3531.
12. Katamura, K.; Shintaku, N.; Yamauchi, Y.; Fukui, T.; Ohshima, Y.; Mayumi, M.; Furusho, K. Prostaglandin E2 at priming of naive CD4+ T cells inhibits acquisition of ability to produce IFN-gamma and IL-2, but not IL-4 and IL-5. J. Immunol. 1995, 155 (10), 4604 – 4612.
13. Snijdewint, F. G.; Kalinski, P.; Wierenga, E. A.; Bos, J. D.; Kapsenberg, M. L. Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes. J. Immunol. 1993, 150 (12), 5321 – 5329.
14. Walker, W.; Rotondo, D. Prostaglandin E2 is a potent regulator of interleukin-12- and interleukin-18-induced natural killer cell interferon-gamma synthesis. Immunology 2004, 111 (3), 298 – 305.
15. Harizi, H.; Norbert, G. Inhibition of IL-6, TNF-alpha, and cyclooxygenase-2 protein expression by prostaglandin E2-induced IL-10 in bone marrow-derived dendritic cells. Cell Immunol. 2004, 228 (2), 99 – 109.
16. Zeidler, R.; Csanady, M.; Gires, O.; Lang, S.; Schmitt, B.; Wollenberg, B. Tumor cell-derived prostaglandin E2 inhibits monocyte function by interfering with CCR5 and Mac-1. FASEB J. 2000, 14 (5), 661 – 668.
17. Huang, M.; Sharma, S.; Mao, J. T.; Dubinett, S. M. Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J. Immunol. 1996, 157 (12), 5512 – 5520.
18. Withnall, M. T.; Pennington, A.; Wiseman, D. Characterisation of cytosolic phospholipase A2 as mediator of the enhanced arachidonic acid release from dimethyl sulphoxide differentiated U937 cells. Biochem. Pharmacol. 1995, 50 (11), 1893 – 1902.
19. Sneyd, J. R. Recent advances in intravenous anaesthesia. Br. J. Anaesth. 2004, 93 (5), 725 – 736.
20. Vanlersberghe, C.; Camu, F. Propofol. Handb. Exp. Pharmacol. 2008, (182), 227 – 252.
21. Chen, R. M.; Chen, T. G.; Chen, T. L.; Lin, L. L.; Chang, C. C.; Chang, H. C.; Wu, C. H. Anti-inflammatory and antioxidative effects of propofol on lipopolysaccharide-activated macrophages. Ann. N. Y. Acad. Sci. 2005, 1042, 262 – 271.
22. Kahraman, S.; Kilinc, K.; Dal, D.; Erdem, K. Propofol attenuates formation of lipid peroxides in tourniquet-induced ischaemia-reperfusion injury. Br. J. Anaesth. 1997, 78 (3), 279 – 281.
23. Aarts, L.; van der Hee, R.; Dekker, I.; de Jong, J.; Langemeijer, H.; Bast, A. The widely used anesthetic agent propofol can replace alpha-tocopherol as an antioxidant. FEBS Lett. 1995, 357 (1), 83 – 85.
24. Ansley, D. M.; Lee, J.; Godin, D. V.; Garnett, M. E.; Qayumi, A. K. Propofol enhances red cell antioxidant capacity in swine and humans. Can. J. Anaesth. 1998, 45 (3), 233 – 239.
25. Cavalca, V.; Colli, S.; Veglia, F.; Eligini, S.; Zingaro, L.; Squellerio, I.; Rondello, N.; Cighetti, G.; Tremoli, E.; Sisillo, E. Anesthetic propofol enhances plasma gamma-tocopherol levels in patients undergoing cardiac surgery. Anesthesiology 2008, 108 (6), 988 – 997.
26. Marik, P. E. Propofol: An immunomodulating agent. Pharmacotherapy 2005, 25 (5 Pt 2), 28S – 33S.
27. Jiang, Y. J.; Lu, B.; Choy, P. C.; Hatch, G. M. Regulation of cytosolic phospholipase A2, cyclooxygenase-1 and -2 expression by PMA, TN Falpha, LPS and M-CSF in human monocytes and macrophages. Mol. Cell Biochem. 2003, 246 (1–2), 31 – 38.
28. Vila-del Sol, V.; Fresno, M. Involvement of TNF and NF-kappa B in the transcriptional control of cyclooxygenase-2 expression by IFN-gamma in macrophages. J. Immunol. 2005, 174 (5), 2825 – 2833.
29. Landino, L. M.; Crews, B. C.; Timmons, M. D.; Morrow, J. D.; Marnett, L. J. Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis. Proc. Natl. Acad. Sci. USA 1996, 93 (26), 15069 – 15074.
30. Kim, S. F.; Huri, D. A.; Snyder, S. H. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 2005, 310 (5756), 1966 – 1970.
31. Chen, R. M.; Wu, G. J.; Tai, Y. T.; Sun, W. Z.; Lin, Y. L.; Jean, W. C.; Chen, T. L. Propofol reduces nitric oxide biosynthesis in lipopolysaccharide-activated macrophages by downregulating the expression of inducible nitric oxide synthase. Arch. Toxicol. 2003, 77 (7), 418 – 423.
32. Weinberg, J. B.; Misukonis, M. A.; Shami, P. J.; Mason, S. N.; Sauls, D. L.; Dittman, W. A.; Wood, E. R.; Smith, G. K.; McDonald, B.; Bachus, K. E.; Haney, A. F.; Granger, D. L. Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): Analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. Blood 1995, 86 (3), 1184 – 1195.
33. Brenneis, C.; Maier, T. J.; Schmidt, R.; Hofacker, A.; Zulauf, L.; Jakobsson, P. J.; Scholich, K.; Geisslinger, G. Inhibition of prostaglandin E2 synthesis by SC-560 is independent of cyclooxygenase 1 inhibition. FASEB(no.) J. 2006, 20 (9), 1352 – 1360.
34. Furukawa, K.; Yamamori, H.; Takagi, K.; Hayashi, N.; Suzuki, R.; Nakajima, N.; Tashiro, T. Influences of soybean oil emulsion on stress response and cell-mediated immune function in moderately or severely stressed patients. Nutrition 2002, 18 (3), 235 – 240.
35. Gonzalez-Correa, J. A.; Cruz-Andreotti, E.; Arrebola, M. M.; Lopez-Villodres, J. A.; Jodar, M.; De La Cruz, J. P. Effects of propofol on the leukocyte nitric oxide pathway: In vitro and ex vivo studies in surgical patients. Naunyn. Schmiedebergs. Arch. Pharmacol. 2008, 376 (5), 331 – 339.
36. Sinha, P.; Clements, V. K.; Fulton, A. M.; Ostrand-Rosenberg, S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res. 2007, 67 (9), 4507 – 4513.
37. Kushida, A.; Inada, T.; Shingu, K. Enhancement of antitumor immunity after propofol treatment in mice. Immunopharmacol. Immunotoxicol. 2007, 29 (3–4), 477 – 486.
38. Larsen, B.; Hoff, G.; Wilhelm, W.; Buchinger, H.; Wanner, G. A.; Bauer, M. Effect of intravenous anesthetics on spontaneous and endotoxin-stimulated cytokine response in cultured human whole blood. Anesthesiology 1998, 89 (5), 1218 – 1227.
39. Takaono, M.; Yogosawa, T.; Okawa-Takatsuji, M.; Aotsuka, S. Effects of intravenous anesthetics on interleukin (IL)-6 and IL-10 production by lipopolysaccharide-stimulated mononuclear cells from healthy volunteers. Acta Anaesthesiol. Scand. 2002, 46 (2), 176 – 179.
40. Hoff, G.; Bauer, I.; Larsen, B.; Bauer, M. Modulation of endo toxin-stimulated TNF-alpha gene expression by ketamine and propofol in cultured human whole blood. Anaesthesist 2001, 50 (7), 494 – 499.
41. Wu, C. H.; Chen, T. L.; Chen, T. G.; Ho, W. P.; Chiu, W. T.; Chen, R. M. Nitric oxide modulates pro- and anti-inflammatory cytokines in lipopolysaccharide-activated macrophages. J. Trauma 2003, 55 (3), 540 – 545.
42. Jiang, Q.; Elson-Schwab, I.; Courtemanche, C.; Ames, B. N. gamma-tocopherol and its major metabolite, in contrast to alpha-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells. Proc. Natl. Acad. Sci. USA 2000, 97 (21), 11494 – 11499.
43. Couper, K. N.; Blount, D. G.; Riley, E. M. IL-10: the master regulator of immunity to infection. J. Immunol. 2008, 180 (9), 5771 – 5777.
44. de Waal Malefyt, R.; Abrams, J.; Bennett, B.; Figdor, C. G.; de Vries, J. E. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocproduced by monocytes. J. Exp. Med. 1991, 174 (5), 1209 – 1220.
45. Slade, M. S.; Simmons, R. L.; Yunis, E.; Greenberg, L. J. Immunodepression after major surgery in normal patients. Surgery 1975, 78 (3), 363 – 372.
46. Walton, B. Effects of anaesthesia and surgery on immune status. Br. J. Anaesth. 1979, 51 (1), 37 – 43.
47. Ogawa, K.; Hirai, M.; Katsube, T.; Murayama, M.; Hamaguchi, K.; Shimakawa, T.; Naritake, Y.; Hosokawa, T.; Kajiwara, T. Suppression of cellular immunity by surgical stress. Surgery 2000, 127 (3), 329 – 336.
48. Inada, T.; Yamanouchi, Y.; Jomura, S.; Sakamoto, S.; Takahashi, M.; Kambara, T.; Shingu, K. Effect of propofol and isoflurane anaesthesia on the immune response to surgery. Anaesthesia 2004, 59 (10), 954 – 959.
49. O’Sullivan, S. T.; Lederer, J. A.; Horgan, A. F.; Chin, D. H.; Mannick, J. A.; Rodrick, M. L. Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. Ann. Surg. 1995, 222 (4), 482 – 492.
50. Decker, D.; Schondorf, M.; Bidlingmaier, F.; Hirner, A.; von Ruecker, A. A. Surgical stress induces a shift in the type-1/type-2 T-helper cell balance, suggesting down-regulation of cell-mediated and up-regulation of antibody-mediated immunity commensurate to the trauma. Surgery 1996, 119 (3), 316 – 325.